6533b85afe1ef96bd12b9794
RESEARCH PRODUCT
Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant.
Massimo TommasinoAnnie ArslanPhilippe BirembautMartha GrodzkiGuillaume BessonChristine ClavelIngeborg ZehbeSilvia Franceschisubject
medicine.medical_specialtyEpidemiologyUterine Cervical NeoplasmsCervical intraepithelial neoplasiaLesionCohort StudiesRisk FactorsInternal medicineEpidemiologymedicineOdds RatioHumansRisk factorbusiness.industryPapillomavirus InfectionsHPV infectionvirus diseasesOdds ratioOncogene Proteins Viralmedicine.diseaseUterine Cervical DysplasiaRepressor ProteinsOncologyCase-Control StudiesImmunologyDisease ProgressionFemaleViral diseaseFrancemedicine.symptombusinessCohort studydescription
Abstract To test the significance of human papillomavirus (HPV) type 16 and HPV16 E6 variants as risk factors for viral persistence and progression to high-grade lesion, we did a nested case-control study within a cohort study of >15,000 Caucasian French women. Three groups infected with high-risk HPV were compared: (a) women with cleared infection (controls, n = 201), (b) women with persistent infection (cases, n = 87), and (c) women who progressed into high-grade lesion (cases, n = 58). Women with persistent HPV infection and those that progressed into high-grade lesions were likelier to harbor HPV16 than other high-risk HPV types [odds ratio (OR), 2.4; 95% confidence interval (95% CI), 1.3-4.3 and OR, 4.2; 95% CI, 2.2-8.1, respectively]. Notably, especially elevated ORs of persistence (3.0; 95% CI, 1.4-6.7) and progression (6.2; 95% CI, 2.7-14.3) were found among women who harbored the HPV16 350G variant. Thus, HPV type and HPV16 variant seem to be risk factors for viral persistence and progression of infections into high-grade cervical lesions. Cancer Epidemiol Biomarkers Prev 2006:15(4);820–2
year | journal | country | edition | language |
---|---|---|---|---|
2006-04-15 | Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology |